Acer Therapeutics Inc

(NASDAQ:ACER)

Latest On Acer Therapeutics Inc (ACER):

Date/Time Type Description Signal Details
2023-03-28 02:31 ESTNewsAcer Therapeutics GAAP EPS of -$0.54 misses by $0.17N/A
2023-03-22 23:01 ESTNewsAcer Therapeutics stock dips on $2.7M securities offeringN/A
2023-03-17 20:16 ESTNewsAcer stock slumps ~45% as ACER-801 paused after hot flashes trial disappoints; cash woesN/A
2023-01-05 19:31 ESTNewsAcer Therapeutics rises on starting trial of ACER-801 in men with adenocarcinoma of the prostateN/A
2022-12-29 14:01 ESTNewsAcer Therapeutics regains compliance with Nasdaq listing ruleN/A
2022-12-27 18:01 ESTNewsAcer Therapeutics down 33% despite winning FDA approval for urea cycle disorders treatmentN/A
2022-12-23 20:16 ESTNewsAcer wins FDA OK for Olpruva to treat urea cycle disordersN/A
2022-11-30 12:46 ESTNewsAcer Therapeutics to privately place $1.5M of securitiesN/A
2022-11-15 14:33 ESTNewsAcer Therapeutics GAAP EPS of -$0.31 beats by $0.37N/A
2022-10-26 12:16 ESTNewsAcer Therapeutics to get US patent for celiprolol use in connective tissue disorderN/A
2022-10-05 17:46 ESTNewsAcer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatmentN/A
2022-08-16 03:46 ESTNewsAcer Therapeutics GAAP EPS of -$0.17 beats by $0.42N/A
2022-08-12 14:16 ESTNewsAcer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EUN/A
2022-07-28 20:02 ESTNewsFDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapyN/A
2022-07-18 23:46 ESTNewsAcer resubmits U.S. marketing application for urea cycle disorder therapyN/A
2022-07-08 14:31 ESTNewsAcer Therapeutics stock rises 10% on Chinese patent for urea cycle disorder therapyN/A
2022-06-27 23:02 ESTNewsAcer Therapeutics begins phase 3 trial of Edsivo to treat rare genetic disorder treatmentN/A
2022-06-21 22:02 ESTNewsAcer Therapeutics promotes Tanya Hayden to the position of COON/A
2022-06-21 22:02 ESTNewsAcer Therapeutics stock down after FDA declines to approve urea cycle disorders treatmentN/A
2022-06-07 23:46 ESTNewsAcer/Relief urea cycle disorder therapy still under FDA review, surpassing target dateN/A
2022-05-17 02:46 ESTNewsAcer Therapeutics GAAP EPS of -$0.65 misses by $0.37N/A
2022-05-10 01:16 ESTNewsAcer Therapeutics reaches agreement with FDA on protocol for phase 3 Edsivo trialN/A
2022-04-27 03:26 ESTNewsAcer Therapeutics regains compliance with Nasdaq listing standardN/A
2022-04-12 07:45 ESTNewsAcer, Relief report data showing bioequivalence of ACER-001 versus reference drugN/A
2022-04-04 13:16 ESTNewsAcer gains on FDA’s Breakthrough status for Edsivo in genetic disorderN/A
2022-03-07 15:01 ESTNewsAcer Therapeutics nabs $48.5M in convertible note and secured loan financing facilitiesN/A
2022-03-03 07:01 ESTNewsAcer Therapeutics GAAP EPS of -$0.31 misses by $0.30, revenue of $0.36M misses by $2.97MN/A
2022-02-01 04:30 ESTNewsAcer Therapeutics secures new U.S. patent for ACER-001 for urea cycle disordersN/A
2021-12-09 15:17 ESTNewsAcer Therapeutics wins FDA nod for hot flashes trialN/A
2021-11-26 11:22 ESTNewsWarning: ACER is at high risk of performing badlyN/A
2021-11-20 03:16 ESTNewsAcer Therapeutics EPS beats by $0.05N/A
2021-10-26 10:46 ESTNewsAcer Therapeutics shares rise after new US patent for ACER-001N/A
2021-10-08 02:32 ESTNewsAcer Therapeutics nabs new U.S. patents for ACER-001 formulationN/A
2021-10-07 03:31 ESTNewsAcer climbs after FDA accepted marketing application for urea cycle disorder therapyN/A
2021-08-31 22:31 ESTNewsAcer Therapeutics: Deriving Value By Developing Therapies For Rare DiseasesN/A
2021-08-10 19:30 ESTNewsAcer Therapeutics EPS beats by $0.13N/A
2021-08-09 22:18 ESTNewsAcer, Relief Therapeutics submit ACER-001 NDA in U.S. for urea cycle disordersN/A
2021-07-20 18:03 ESTNewsAcer Therapeutics plans NDA submission for ACER-001 in Q3 2021N/A
2021-07-20 17:48 ESTNewsAcer Therapeutics plans clinical trial of Edsivo in connective​-tissue disorderN/A
2021-03-22 21:48 ESTNewsRelief and Acer ink ACER-001 collaboration and license agreementN/A
2021-03-04 16:46 ESTNewsAcer Therapeutics down 10% on share offeringN/A
2021-03-04 07:01 ESTFinancialsCompany financials have been released.Neutral
2021-03-02 07:01 ESTEarnings EstimateAn EPS average of -$1.66 is estimated for the 2022 year.Sell
2021-03-02 07:01 ESTEarnings EstimateAn EPS average of -$0.40 is estimated for the quarter ending on June 30, 2021.Buy
2021-01-25 12:32 ESTNewsRelief Therapeutics and Acer ink option agreement for development of ACER-001N/A
2020-12-22 15:17 ESTNewsAcer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disordersN/A
2020-11-25 11:02 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 11:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-13 11:01 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 11:01 ESTEarnings EstimateAn EPS average of -$0.40 is estimated for the quarter ending on March 31, 2021.Buy

About Acer Therapeutics Inc (ACER):

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 2013 and is headquartered in Newton, Massachusetts.

ACER Quotes by TradingView

See Advanced Chart

General

  • Name Acer Therapeutics Inc
  • Symbol ACER
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 20
  • Last Split Factor96:1000
  • Last Split Date2017-09-21
  • Fiscal Year EndDecember
  • IPO Date2017-09-22
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.acertx.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 5.99
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.01
  • Next Year EPS Estimate -$1.95
  • Next Quarter EPS Estimate -$0.40
  • Return on Assets -79%
  • Return on Equity -172%
  • Earnings Per Share -$3.20
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 49.23 million
  • EBITDA -30604760
  • Analyst Target Price $10
  • Book Value Per Share $0.62
View More

Share Statistics

  • Shares Outstanding 14.31 million
  • Shares Float 6.92 million
  • % Held by Insiders 2521%
  • % Held by Institutions 37.47%
  • Shares Short 91753
  • Shares Short Prior Month 126104
  • Short Ratio 0.23
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.24
  • 52 Week High $5.84
  • 52 Week Low $1.08
  • 50 Day Moving Average 3.52
  • 200 Day Moving Average 2.94
View More

Dividends

  • Dividend Date 2017-09-21
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Acer Therapeutics Inc (ACER) Dividend Calendar:

ACER's last dividend payment was made to shareholders on September 21, 2017.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Acer Therapeutics Inc (ACER) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-01$N/A-$0.50-$0.41-22.7%
2020-09-302020-11-10$N/A-$0.51-$0.46-10.87%
2020-06-302020-08-13$N/A-$0.56-$0.40-41.77%
2020-03-312020-05-14$N/A-$0.49-$0.40-23.27%
2019-12-312020-03-18$N/A-$0.51-$0.49-4.08%
2019-09-302019-11-13$N/A-$0.52-$0.520.38%
2019-06-302019-08-13$N/A-$0.95-$0.74-27.1%
2019-03-312019-05-14$N/A-$0.79-$0.823.19%
2018-12-312019-03-07$N/A-$0.85-$0.47-80.85%
2018-09-302018-11-09$N/A-$0.43-$0.5420.37%
2018-06-302018-08-13$N/A-$0.64-$0.55-16.9%
2018-03-312018-05-14$N/A-$0.53-$0.6923.19%
2017-12-312018-03-07$N/A-$0.63-$0.52-21.65%
2017-09-302017-11-13$N/A-$1.09-$1.2412.1%
2017-06-302017-08-14$N/A-$0.93-$1.2425%
2017-03-312017-05-12$N/A-$1.24-$1.358.15%
2016-12-312017-03-28$N/A-$0.93-$2.6164.37%
2016-09-302016-11-14$N/A-$2.90-$2.61-11.11%
2016-06-302016-08-11$N/A-$3.11-$2.42-28.51%
2016-03-312016-05-12$N/A-$3.21-$3.6211.33%
2015-12-312016-03-15$N/A-$3.11-$5.1839.96%
2015-09-302015-11-10$N/A-$4.35-$18.7876.84%
2015-06-302015-08-12$N/A-$0.56-$0.6412.5%
2015-03-312015-05-12$N/A-$0.96-$1.2020%
2014-12-312015-02-23$N/A-$0.96-$1.1214.29%
2014-09-302014-11-06$N/A-$1.12-$1.163.45%
2014-06-302014-08-14$N/A-$12.43-$10.36-19.98%
2014-03-312014-05-14$N/A-$10.77-$10.770%
2012-12-312013-03-05$N/A-$29.13
2012-09-302012-11-02$N/A-$33.90
2012-06-302012-08-13$N/A-$31.12
2012-03-312012-05-11$N/A-$34.13
2011-12-312012-03-06-$27.60
2011-09-302011-11-04$N/A-$18.65
2011-06-302011-08-11$N/A-$19.88-$23.2014.31%
2011-03-312011-05-06-$19.88-$16.57-19.98%
2010-12-312011-03-08-$18.14
2010-09-302010-11-09-$23.22
2010-06-302010-08-06-$39.77-$26.51-50.02%
2010-03-312010-05-13-$29.82-$26.51-12.49%
2009-12-312010-03-05-$30.45
2009-09-302009-11-04$44.00
2009-06-302009-08-13-$23.37
2009-03-312009-05-15-$44.30
2008-09-302008-10-23-$92.79-$102.739.68%
2008-06-302008-08-14-$119.30-$125.925.26%
2008-03-312008-05-13-$122.61-$162.3724.49%
2007-12-312008-03-18-$71.98
2007-09-302007-11-05-$194.20
2007-06-302007-08-14-$242.77
2007-03-312007-05-15-$216.83
2006-12-312007-03-19$29.82-$195.51115.25%
2006-09-302006-11-13-$65.89
2006-06-302006-08-14-$465.05
2006-03-312006-03-31-$316.12
2005-12-312005-12-31$149.20
2005-09-302005-09-30-$764.73
2005-06-302005-06-30-$2,316.73
2005-03-312005-03-31-$1,214.51
2004-12-312004-12-31-$1,391.79
2004-09-302004-09-30-$281.44
2004-06-302004-06-30-$370.38
2004-03-312004-03-31-$21,523.18
2002-06-302002-06-30-$1,744.24
2002-03-312002-03-31-$1,768.73
2001-12-312001-12-31-$2,078.78
2001-06-302001-06-30-$3,443.74
2001-03-312001-03-31-$4,398.92
2000-12-312000-12-31-$5,175.19

Acer Therapeutics Inc (ACER) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Acer Therapeutics Inc (ACER) Chart:

Acer Therapeutics Inc (ACER) News:

Below you will find a list of latest news for Acer Therapeutics Inc (ACER) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Acer Therapeutics Inc (ACER) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest ACER Trades:

Date Shares Price
Jun 13, 2022 3:46 PM EST100$1.82

Acer Therapeutics Inc (ACER) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020030269/0001564590-20-030269-index.htm
2018-03-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000018009070/0000000000-18-009070-index.htm
2018-03-30UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000018009687/0000000000-18-009687-index.htm
2018-04-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000018009820/0000000000-18-009820-index.htm
2018-11-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000018035607/0000000000-18-035607-index.htm
2020-05-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000020004725/0000000000-20-004725-index.htm
2020-06-02UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000020004906/0000000000-20-004906-index.htm
2020-06-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1069308/000000000020004984/0000000000-20-004984-index.htm
2018-08-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000101297518001040/0001012975-18-001040-index.htm
2019-04-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1069308/000106299319001799/0001062993-19-001799-index.htm
2018-08-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1069308/000107261318000451/0001072613-18-000451-index.htm
2018-08-24SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1069308/000107261318000452/0001072613-18-000452-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000110465920019172/0001104659-20-019172-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000114420419007802/0001144204-19-007802-index.htm
2018-03-28PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1069308/000119312518099657/0001193125-18-099657-index.htm
2018-03-28CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312518099664/0001193125-18-099664-index.htm
2018-03-30PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1069308/000119312518103224/0001193125-18-103224-index.htm
2018-03-30CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312518103226/0001193125-18-103226-index.htm
2018-04-09DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1069308/000119312518110876/0001193125-18-110876-index.htm
2018-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000119312518233135/0001193125-18-233135-index.htm
2018-07-31424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1069308/000119312518233142/0001193125-18-233142-index.htm
2018-08-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000119312518235008/0001193125-18-235008-index.htm
2018-08-01424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1069308/000119312518235020/0001193125-18-235020-index.htm
2018-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000119312518238286/0001193125-18-238286-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000119312518323804/0001193125-18-323804-index.htm
2018-11-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1069308/000119312518323807/0001193125-18-323807-index.htm
2018-11-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312518329893/0001193125-18-329893-index.htm
2018-11-23424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1069308/000119312518332710/0001193125-18-332710-index.htm
2019-03-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1069308/000119312519067328/0001193125-19-067328-index.htm
2019-04-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1069308/000119312519105159/0001193125-19-105159-index.htm
2020-03-18S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1069308/000119312520077332/0001193125-20-077332-index.htm
2020-03-18424B2Prospectus [Rule 424(b)(2)]https://www.sec.gov/Archives/edgar/data/1069308/000119312520077337/0001193125-20-077337-index.htm
2020-05-12S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1069308/000119312520140384/0001193125-20-140384-index.htm
2020-06-01S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1069308/000119312520157242/0001193125-20-157242-index.htm
2020-06-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312520157256/0001193125-20-157256-index.htm
2020-06-03S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1069308/000119312520159485/0001193125-20-159485-index.htm
2020-06-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312520159495/0001193125-20-159495-index.htm
2020-06-03CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312520159504/0001193125-20-159504-index.htm
2020-06-05S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1069308/000119312520161893/0001193125-20-161893-index.htm
2020-06-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312520161899/0001193125-20-161899-index.htm
2020-06-05CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1069308/000119312520161933/0001193125-20-161933-index.htm
2020-06-08424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1069308/000119312520163183/0001193125-20-163183-index.htm
2020-08-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1069308/000119312520208037/0001193125-20-208037-index.htm
2020-10-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1069308/000119312520269199/0001193125-20-269199-index.htm
2018-04-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919118025839/0001209191-18-025839-index.htm
2018-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919118025840/0001209191-18-025840-index.htm
2018-12-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919118061392/0001209191-18-061392-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919118061395/0001209191-18-061395-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007236/0001209191-19-007236-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007238/0001209191-19-007238-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007239/0001209191-19-007239-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007240/0001209191-19-007240-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007241/0001209191-19-007241-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007243/0001209191-19-007243-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007244/0001209191-19-007244-index.htm
2019-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119007245/0001209191-19-007245-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119016770/0001209191-19-016770-index.htm
2019-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119041332/0001209191-19-041332-index.htm
2019-09-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050500/0001209191-19-050500-index.htm
2019-09-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050502/0001209191-19-050502-index.htm
2019-09-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050504/0001209191-19-050504-index.htm
2019-09-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050506/0001209191-19-050506-index.htm
2019-09-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050508/0001209191-19-050508-index.htm
2019-09-253Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050614/0001209191-19-050614-index.htm
2019-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919119050616/0001209191-19-050616-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120000814/0001209191-20-000814-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120000860/0001209191-20-000860-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120000887/0001209191-20-000887-index.htm
2020-01-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120000915/0001209191-20-000915-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120016083/0001209191-20-016083-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120043802/0001209191-20-043802-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120043803/0001209191-20-043803-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120043804/0001209191-20-043804-index.htm
2020-07-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120043805/0001209191-20-043805-index.htm
2020-07-29DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1069308/000120919120043937/0001209191-20-043937-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000121390020003668/0001213900-20-003668-index.htm
2018-04-0525-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or rethttps://www.sec.gov/Archives/edgar/data/1069308/000135445718000080/0001354457-18-000080-index.htm
2020-05-19SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000138713120004964/0001387131-20-004964-index.htm
2020-08-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000138713120007103/0001387131-20-007103-index.htm
2018-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018013411/0001564590-18-013411-index.htm
2018-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459018013413/0001564590-18-013413-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018013619/0001564590-18-013619-index.htm
2018-05-158-A12B/ARegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1069308/000156459018013627/0001564590-18-013627-index.htm
2018-05-15S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1069308/000156459018013641/0001564590-18-013641-index.htm
2018-06-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018016427/0001564590-18-016427-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018021459/0001564590-18-021459-index.htm
2018-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459018021463/0001564590-18-021463-index.htm
2018-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018022587/0001564590-18-022587-index.htm
2018-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018023562/0001564590-18-023562-index.htm
2018-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018025334/0001564590-18-025334-index.htm
2018-11-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018028920/0001564590-18-028920-index.htm
2018-11-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459018028926/0001564590-18-028926-index.htm
2018-12-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459018031377/0001564590-18-031377-index.htm
2019-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019000015/0001564590-19-000015-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019000295/0001564590-19-000295-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1069308/000156459019006779/0001564590-19-006779-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019006822/0001564590-19-006822-index.htm
2019-04-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019010844/0001564590-19-010844-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019019129/0001564590-19-019129-index.htm
2019-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459019019149/0001564590-19-019149-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019020160/0001564590-19-020160-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019023312/0001564590-19-023312-index.htm
2019-07-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019024572/0001564590-19-024572-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019028533/0001564590-19-028533-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019031800/0001564590-19-031800-index.htm
2019-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459019031810/0001564590-19-031810-index.htm
2019-08-198-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019032528/0001564590-19-032528-index.htm
2019-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019038182/0001564590-19-038182-index.htm
2019-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459019043229/0001564590-19-043229-index.htm
2019-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019043239/0001564590-19-043239-index.htm
2019-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459019046549/0001564590-19-046549-index.htm
2020-01-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020000119/0001564590-20-000119-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020006030/0001564590-20-006030-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020011609/0001564590-20-011609-index.htm
2020-03-1810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1069308/000156459020011639/0001564590-20-011639-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020020178/0001564590-20-020178-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020024186/0001564590-20-024186-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020025460/0001564590-20-025460-index.htm
2020-05-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459020025470/0001564590-20-025470-index.htm
2020-06-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020030269/0001564590-20-030269-index.htm
2020-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020032038/0001564590-20-032038-index.htm
2020-07-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020032311/0001564590-20-032311-index.htm
2020-07-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020033468/0001564590-20-033468-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020035306/0001564590-20-035306-index.htm
2020-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020040013/0001564590-20-040013-index.htm
2020-08-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1069308/000156459020040040/0001564590-20-040040-index.htm
2020-09-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1069308/000156459020042081/0001564590-20-042081-index.htm
2018-09-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000161577418009610/0001615774-18-009610-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1069308/000161577419002510/0001615774-19-002510-index.htm
2018-11-21EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1069308/999999999518002955/9999999995-18-002955-index.htm
2020-06-05EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1069308/999999999520001354/9999999995-20-001354-index.htm
2019-02-15CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1069308/999999999719000377/9999999997-19-000377-index.htm

Acer Therapeutics Inc (ACER) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Acer Therapeutics Inc (ACER). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2521%
Institutional Ownership: 3747%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-24Donald JosephChief Legal Officer and SecyBuy14,285.003.5049,997.5014,285.00https://www.sec.gov/Archives/edgar/data/1069308/000120919120043803/0001209191-20-043803-index.htm
2018-08-01Life Science Ventures VII L.P. TVMDirectorBuy275,000.0018.004,950,000.001,697,709.00https://www.sec.gov/Archives/edgar/data/1069308/000101297518001040/0001012975-18-001040-index.htm
2019-07-03STEVE ASELAGEDirectorBuy5,000.003.7218,581.0018,905.00https://www.sec.gov/Archives/edgar/data/1069308/000120919119041332/0001209191-19-041332-index.htm
2020-07-24Chris SchellingPresident & CEOBuy142,857.003.50499,999.501,892,857.00https://www.sec.gov/Archives/edgar/data/1069308/000120919120043802/0001209191-20-043802-index.htm
2020-07-24JOHN MICHAEL DUNNDirectorBuy21,428.003.5074,998.0027,380.00https://www.sec.gov/Archives/edgar/data/1069308/000120919120043804/0001209191-20-043804-index.htm
2020-07-24STEVE ASELAGEDirectorBuy45,000.003.50157,500.0063,905.00https://www.sec.gov/Archives/edgar/data/1069308/000120919120043805/0001209191-20-043805-index.htm
2019-03-01William T. AndrewsChief Medical OfficerBuy9,000.009,000.00https://www.sec.gov/Archives/edgar/data/1069308/000120919119016770/0001209191-19-016770-index.htm